Showing 1 - 16 results of 16 for search 'Taweegrit Siripongboonsitti', query time: 0.05s Refine Results
  1. 1
    The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)

    The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Paruspak Payoong, Nithi Mahanonda

    Published 2023-12-01
    Get full text
    Article
  2. 2
    A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)

    A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV) by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Panisadee Avirutnan, Kunlakanya Jitobaom, Prasert Auewarakul

    Published 2024-05-01
    Get full text
    Article
  3. 3
    Early antibiotics administration reduces mortality in sepsis patients in tertiary care hospital

    Early antibiotics administration reduces mortality in sepsis patients in tertiary care hospital by Suramath Isaranuwatchai, Jirawat Buppanharun, Thamonwan Thongbun, Kaewklao Thavornwattana, Monprach Harnphadungkit, Taweegrit Siripongboonsitti

    Published 2025-01-01
    Get full text
    Article
  4. 4
    Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)

    Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients... by Taweegrit Siripongboonsitti, Nuttakant Nontawong, Kriangkrai Tawinprai, Ornpreya Suptawiwat, Kamonwan Soonklang, Yong Poovorawan, Nithi Mahanonda

    Published 2023-12-01
    Get full text
    Article
  5. 5
    Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST)

    Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged... by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Thachanun Porntharukcharoen, Supamas Sirisreetreerux, Thitapha Thongchai, Kamonwan Soonklang, Nithi Mahanonda

    Published 2024-07-01
    Get full text
    Article
  6. 6
    The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

    The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study by Nuttakant Nontawong, Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Mana Boonpratoom, Nawin Krailassiri, Chayaporn Boonkhum, Kamonwan Soonklang, Yong Poovorawan, Nithi Mahanonda

    Published 2022-11-01
    Get full text
    Article
  7. 7
    Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)

    Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV) by Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Kaewklao Thavornwattana, Nithi Mahanonda

    Published 2023-09-01
    Get full text
    Article
  8. 8
    Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)

    Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized... by Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Tararin Nimmol, Mullika Buttakosa, Gaidganok Sornsamdang, Tanadul Jarrusrojwuttikul, Phumin Silapant, Nithi Mahanonda

    Published 2023-09-01
    Get full text
    Article
  9. 9
    Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

    Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population by Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Harnphadungkit Monprach, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda

    Published 2022-01-01
    Get full text
    Article
  10. 10
    Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

    Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study by Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul

    Published 2023-01-01
    Get full text
    Article
  11. 11
    The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study

    The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Coho... by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Kunsuda Cheirsilpa, Teerapat Ungtrakul, Wasanai Krisorakun, Chanisa Chotipanich, Nat Wimolsiri, Permpen Noitun, Netnapis Srirattana, Nithi Mahanonda

    Published 2023-06-01
    Get full text
    Article
  12. 12
    Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev)

    Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev) by Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda

    Published 2024-12-01
    Get full text
    Article
  13. 13
    Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

    Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines by Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda

    Published 2022-11-01
    Get full text
    Article
  14. 14
    The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study

    The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study by Thachanun Porntharukchareon, Wipada Chartisathian, Manassamon Navinpipat, Chayanee Samdaengpan, Kunsuda Cheirsilpa, Aimwipa Lueprasitsakul, Supanat Worawichawong, Viroj Muangsillapasart, Pratya Pumuthaivirat, Bothamai Dechates, Supamas Sirisreetreerux, Taweegrit Siripongboonsitti, Vimonsri Rangsrisaeneepitak, Kerati Jirawattanapalin, Kriangkrai Tawinprai

    Published 2023-08-01
    Get full text
    Article
  15. 15
    Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study

    Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study by Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Preeda Vanichsetakul, Saraiorn Thonginnetra, Krongkwan Niemsorn, Pathariya Promsena, Manunya Tandhansakul, Naruporn Kasemlawan, Natthanan Ruangkijpaisal, Narin Banomyong, Nanthida Phattraprayoon, Teerapat Ungtrakul, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Nithi Mahanonda

    Published 2022-05-01
    Get full text
    Article
  16. 16
    Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand

    Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand by Nicolas Salvadori, Gonzague Jourdain, Rungroj Krittayaphong, Taweegrit Siripongboonsitti, Subsai Kongsaengdao, Kriangsak Atipornwanich, Parichart Sakulkonkij, Nasikarn Angkasekwinai, Rujipas Sirijatuphat, Sarunyou Chusri, Tanavit Mekavuthikul, Anucha Apisarnthanarak, Sirawat Srichatrapimuk, Somnuek Sungkanuparph, Suppachok Kirdlarp, Thanyakamol Phongnarudech, Suraphan Sangsawang, Panuwat Napinkul, Jullapong Achalapong, Suwimon Khusuwan, Piyanut Pratipanawat, Pornboonya Nookeu, Namphol Danpipat, Pornvimol Leethong, Piya Hanvoravongchai, Pra-ornsuda Sukrakanchana, Prasert Auewarakul

    Published 2024-06-01
    Get full text
    Article

Search Tools: